Preventive Balloon Dilation Proven to Save Lives: Landmark Nordic Study Published in The Lancet
Cardiovascular disease remains the leading cause of death in Sweden, claiming approximately 30,000 lives annually and affecting tens of thousands more through non-fatal heart attacks—over 20,000 each year. In a significant advance for preventive cardiology, a comprehensive new meta-analysis led by researchers at Karolinska Institutet and Danderyd Hospital has conclusively demonstrated that preventive balloon angioplasty (also known as percutaneous coronary intervention, or PCI) significantly reduces both mortality and the risk of subsequent heart attacks in high-risk patients.
The study, now published in The Lancet, synthesizes data from six randomized controlled trials involving more than 8,000 patients worldwide. It marks a turning point in clinical guidance, resolving years of scientific uncertainty about the value of treating non-culprit lesions—narrowed but not yet fully blocked coronary arteries—during the same procedure as an emergency PCI for an acute heart attack.
“Up until now, the medical community has debated whether addressing these additional vulnerable plaques offers real clinical benefit,” explains Dr. Felix Böhm, senior physician and researcher at both Karolinska Institutet and Danderyd Hospital, and lead author of the meta-analysis. “Our findings are unequivocal: preventive balloon dilation in selected patients cuts the risk of death and repeat myocardial infarctions by a statistically and clinically significant margin.”
Why This Matters
During an acute heart attack, standard care involves emergency PCI to reopen the completely blocked coronary artery causing the event. However, imaging studies reveal that roughly half of these patients also harbour additional partially obstructed vessels—so-called non-culprit lesions—that are at high risk of future rupture or occlusion. Left untreated, these silent threats can trigger recurrent cardiac events, often within months.
Historically, guidelines have advised either medical management alone or staged interventions weeks later. But this new evidence supports a more proactive, single-procedure approach: treating the culprit lesion and significant non-culprit lesions during the initial hospitalisation.
A Nordic Leadership Moment
Sweden has been at the forefront of adopting this integrated approach in clinical practice, with centres like Danderyd Hospital pioneering its implementation. The publication of this rigorous meta-analysis not only validates Sweden’s clinical protocols but also provides a robust evidence base for global adoption.
“This isn’t just a Swedish success—it’s a patient-centred advance with worldwide implications,” Dr. Böhm emphasizes. “By confirming that preventive PCI improves survival, we can now advocate for standardized, guideline-backed use of this intervention across health systems, from Oslo to Osaka.”
Economic and Systemic Implications
Beyond clinical outcomes, the findings carry substantial health-economic weight. Preventing repeat heart attacks reduces hospital readmissions, long-term disability, and the need for complex revascularization surgeries—all of which strain healthcare budgets. In the Nordic context, where value-based healthcare and preventive strategies are policy priorities, this research reinforces the cost-effectiveness of early, comprehensive intervention.
Experts estimate that if adopted universally, preventive PCI could prevent hundreds of deaths annually across the Nordic region alone—and tens of thousands globally.
Looking Ahead
The Karolinska–Danderyd team is now collaborating with the European Society of Cardiology to update clinical guidelines, and discussions are underway with regulatory bodies to ensure equitable access to intravascular imaging tools—such as fractional flow reserve (FFR) and optical coherence tomography (OCT)—which help identify which non-culprit lesions warrant intervention.
As Dr. Böhm concludes: “This is what precision cardiology looks like in action—using evidence, technology, and timely intervention to not just treat disease, but prevent it. For patients, that means more years of life, with better quality.”
The Nordic Business Journal will continue to track the implementation of these findings across public health systems and their impact on cardiovascular care policy in the region.